U.S. markets open in 2 hours 53 minutes

Nicox S.A. (COX.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
4.4350-0.0750 (-1.66%)
As of 12:17PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.5100
Open4.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.3550 - 4.4850
52 Week Range2.5300 - 6.2700
Volume138,772
Avg. Volume360,412
Market Cap164.229M
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-0.6250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Nicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma
      GlobeNewswire

      Nicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

      Press ReleaseNicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma February 15, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion of ZERVIATE®, indicated for the treatment of ocular itching associated with allergic conjunctivitis. Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties. Hikma has strong and well-established U.S. commercial capabilities with medical sales representatives deployed across the country, serving the needs of general practitioners and family doctors. Hikma is a top-10 U.S. generic pharmaceutical company, developing, manufacturing and distributing a broad range of branded and non-branded generic medicines for customers and partners. Eyevance will continue to promote ZERVIATE to ophthalmology and optometry healthcare professionals in the U.S. Nicox and Eyevance have a license agreement for the commercialization of ZERVIATE in the U.S., where the product has been marketed since March 2020. Gavin Spencer, Chief Business Officer of Nicox, said: “This creative deal by Eyevance, executed in good time for the crucial U.S. spring allergy season, expands their reach to include healthcare professionals outside eyecare, such as allergists, general and family practitioners and pediatricians, who account for around 40% of the 1 million prescriptions for branded allergy products in the United States. The partnership may thus lead to an increase in sales and demonstrates Eyevance’s strong commitment to maximizing the value of the ZERVIATE franchise in the United States.” Under Nicox’s licensing agreement with Eyevance, Nicox is eligible for up to $37.5 million in milestones payable on Eyevance achieving pre-defined sales targets, with $30 million of these milestones being triggered by annual sales of $100 million and above. Nicox also receives tiered royalties1 of 8% to 15% on net sales of ZERVIATE in the U.S., including those made as a result of promotion by HIKMA. Eyevance is responsible for all manufacturing, regulatory and commercialization activities for ZERVIATE in the United States, where ZERVIATE is protected by patents expected to remain in force until 2030 and 2032. About Hikma Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com. About ZERVIATE ZERVIATE® (cetirizine ophthalmic solution), 0.24% is a novel formulation of cetirizine developed and approved for the first time for topical application in the eye for the treatment of ocular itching associated with allergic conjunctivitis. Cetirizine, the active ingredient in ZYRTEC®, is a second-generation antihistamine (H1 receptor antagonist) that binds competitively to histamine receptor sites. Cetirizine, in approved oral formulations, has a well-characterized systemic efficacy and safety profile with worldwide exposure resulting from 20 years of oral use. ZERVIATE was developed by Nicox as the first and only formulation of cetirizine for topical application in the eye. For further details of ZERVIATE in the U.S., please go to www.myzerviate.com. ZERVIATE is also licensed exclusively to Ocumension Therapeutics in the Chinese and South East Asian markets, Samil Pharmaceutical in South Korea and ITROM Pharmaceutical Group for Gulf and Arab Markets. About Allergic Conjunctivitis Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis. Conjunctivitis is an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids. It may affect one or both eyes. The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light.About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage Bryan, Garnier & Co Victor Floc’h Paris, FranceCantor Fitzgerald Louise Chen New York, U.S.Edison Investment Research Pooya Hemami London, UKH.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Damien Choplain Paris, France The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853mchang@lifesciadvisors.comMediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 sophie@lifesciadvisors.comForward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox’s website (www.nicox.com) and (ii) as restated in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website.Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 1 Nicox committed to pay to Eyevance certain manufacturing costs, which will be deducted from these royalty payments, reducing the effective royalty initially to 5% net until such costs are paid Attachment EN_ZERVIATEEyevanceNonOphthaCoPromote_PR_20210215_F

    • Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea
      PR Newswire

      Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea

      Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, a leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Ministry of Food and Drug Safety in South Korea.

    • Number of voting rights as of January 31, 2021
      GlobeNewswire

      Number of voting rights as of January 31, 2021

      Nicox SASociété anonyme with a registered capital of € 37,030,335 Head Office:DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On February 1, 2021, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of January 31, 2021Total number of shares composing the share capital37,030,335Total number of voting rights37,030,335Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights37,030,335 ---------------www.nicox.comPhone: +33 4-97-24-53-00Fax : +33 4-97-24-53-99 Attachment 31 jan 21 EN